Turning Point Brands Stock Earnings Reports

Turning Point Brands reported strong Q1 2026 momentum driven by Modern Oral (nicotine pouches). Modern Oral gross sales rose 167% YoY and net sales 133% YoY, now representing 42% of consolidated net sales (vs. 21% a year ago). Management raised full-year 2026 Modern Oral guidance to gross sales of $280M–$300M and net sales of $210M–$225M (previously $220M–$240M and $180M–$190M, respectively). Company introduced full-year EBITDA guidance of $70M–$90M while planning significant front‑loaded investments in sales force and brand marketing ($80M–$105M in 2026). Q1 adjusted EBITDA was $25.9M (20.8% margin) and consolidated sales were $124.3M (up 17% YoY). First-quarter free cash flow was negative $27.4M as TPB invests in trade, marketing, working capital and U.S. manufacturing (Louisville plant commissioning underway); cash balance was $192.4M. Management expects to be roughly cash‑flow breakeven for the remainder of 2026. Key strategic points: aggressive retail expansion (store count expected to grow ~70% YoY by year-end), focus on winning in nicotine pouches (FRE and ALP brands), committing to domestic manufacturing to improve unit economics, and PMTA regulatory process ongoing (timing uncertain). Risks/near‑term tradeoffs: margin compression from contra/rebate and slotting fees as retail rollouts accelerate, higher SG&A from marketing and sales coverage, and negative near-term free cash flow as investments ramp.